Recruiting

Testing a new knee injection to reduce osteoarthritis pain

Plain-English translation of NCT07513415 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new injectable treatment called ALLOHEAL designed to relieve pain and improve function in people with knee osteoarthritis. The medication contains three active ingredients—PN, chitosan, and collagen—that work together to reduce inflammation and cushion the knee joint. Researchers want to confirm that this treatment is safe and works as well as or better than current standard treatments.

Many people with knee osteoarthritis don't get adequate pain relief from current treatments, and this medication offers a potentially less invasive option than surgery. The trial will help determine whether this new injection is a safe and effective choice for patients seeking alternatives to manage their knee pain.

Do you qualify?

You likely qualify if…

you are between 40 and 79 years old
you have been diagnosed with knee osteoarthritis in the past 6 months or at your screening visit
you have experienced knee pain for at least 8 weeks
your knee pain score is at least 40 on a pain scale (0–100) at screening
you can walk without a walker or cane (or have been using the same device consistently for at least 6 months)
your body mass index is less than 35

You likely don't qualify if…

you have had surgery or arthroscopic treatment on your target knee within the past 6 months
you currently need surgery on your target knee
you have significant ligament instability or severe joint deformities in your knee
you have other joint conditions (like rheumatoid arthritis, gout, or hip osteoarthritis) that could affect how your knee pain is assessed
you have a history of joint fractures or infections in the target knee

What participation looks like

If you qualify, you will receive an injection of the new medication directly into your knee joint at your first visit. You'll then attend follow-up visits at 6, 10, 16, and 24 weeks to allow researchers to measure how much your pain improves and monitor for any side effects. Throughout the trial, your pain levels and knee function will be assessed using standard questionnaires and physical exams.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

South Korea

Seok Jung Kim, Uijeongbu-si